Roger A. Barker

List of Publications by Citations

385 papers	26,102 citations	85 h-index	149 g-index
420 ext. papers	30,610 ext. citations	7.6 avg, IF	7.13 L-index

#	Paper	IF	Citations
385	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Movement Disorders*, **2012**, 27, 349-56	7	1373
384	A functional role for adult hippocampal neurogenesis in spatial pattern separation. *Science*, **2009**, 325, 210-3	33.3	1167
383	Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. *Brain*, **2007**, 130, 1787-98	11.2	705
382	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. *Brain*, **2009**, 132, 2958-69	11.2	701
381	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. *Lancet Neurology, The*, **2010**, 9, 1200-1213	24.1	618
380	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. *Brain*, **2004**, 127, 550-60	11.2	523
379	Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. *Cell*, **2016**, 167, 566-580.e19	36.2	425
378	Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. *Journal of Neuroscience*, **2003**, 23, 6351-6	6.6	419
377	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1258-64	5.5	416
376	L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. *Neuropsychologia*, **2003**, 41, 1431-41	3.2	403
375	Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. *Brain*, **2002**, 125, 584-94	11.2	341
374	Microglial activation in presymptomatic Huntington's disease gene carriers. *Brain*, **2007**, 130, 1759-66	11.2	324
373	Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. *Journal of Neuroscience*, **2005**, 25, 157-63	6.6	322
372	Targeting Huntingtin Expression in Patients with Huntington's Disease. *New England Journal of Medicine*, **2019**, 380, 2307-2316	59.2	319
371	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. *Lancet, The*, **2014**, 383, 1138-46	40	313
370	Mechanisms of cognitive set flexibility in Parkinson's disease. *Brain*, **2001**, 124, 2503-12	11.2	283
369	The spectrum of nonmotor symptoms in early Parkinson disease. *Neurology*, **2013**, 80, 276-81	6.5	281

368	Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. *Neurodegenerative Diseases*, **2013**, 11, 79-92	2.3	281
367	Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. *Lancet Neurology, The*, **2013**, 12, 84-91	24.1	242
366	Sleep and circadian rhythm regulation in early Parkinson disease. *JAMA Neurology*, **2014**, 71, 589-595	17.2	237
365	L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. *Neuropsychopharmacology*, **2007**, 32, 180-9	8.7	230
364	Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. *Neuropsychologia*, **2005**, 43, 823-32	3.2	226
363	Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. *Movement Disorders*, **2014**, 29, 195-202	7	224
362	Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. *Annals of Neurology*, **2007**, 62, 145-53	9.4	223
361	Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. *European Journal of Neuroscience*, **2004**, 19, 755-60	3.5	213
360	'The clocks that time us'--circadian rhythms in neurodegenerative disorders. *Nature Reviews Neurology*, **2014**, 10, 683-93	15	209
359	A pathophysiological model of freezing of gait in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15, 333-8	3.6	209
358	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. *Brain*, **2013**, 136, 392-9	11.2	201
357	Cell-based therapies for Parkinson disease□past insights and future potential. *Nature Reviews Neurology*, **2015**, 11, 492-503	15	197
356	Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. *Cell Stem Cell*, **2017**, 21, 569-573	18	193
355	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. *Brain*, **2003**, 126, 1127-35	11.2	180
354	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. *Human Molecular Genetics*, **2011**, 20, 345-53	5.6	178
353	A cell atlas of human thymic development defines T cell repertoire formation. *Science*, **2020**, 367,	33.3	171
352	Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. *Lancet Neurology, The*, **2014**, 13, 1193-201	24.1	159
351	Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. *Journal of Neuroscience*, **2007**, 27, 4832-8	6.6	159

350	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 8754-9	11.5	158
349	Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. *Brain*, **2006**, 129, 877-86	11.2	155
348	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. *Annals of Neurology*, **2016**, 80, 674-685	9.4	154
347	Immune problems in central nervous system cell therapy. *NeuroRx*, **2004**, 1, 472-81		154
346	The natural history of treated Parkinson's disease in an incident, community based cohort. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1112-8	5.5	153
345	Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition. *Brain*, **2008**, 131, 2094-105	11.2	153
344	Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. *Neuropsychologia*, **2003**, 41, 645-54	3.2	151
343	The heterogeneity of idiopathic Parkinson's disease. *Journal of Neurology*, **2002**, 249, 138-45	5.5	149
342	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. *Human Brain Mapping*, **2011**, 32, 258-70	5.9	147
341	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. *Brain*, **2015**, 138, 2974-86	11.2	146
340	Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. *Annals of Neurology*, **2015**, 78, 160-77	9.4	146
339	Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. *Brain*, **2008**, 131, 397-408	11.2	145
338	Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 678-85	5.5	144
337	Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. *European Journal of Neuroscience*, **2006**, 23, 1829-38	3.5	141
336	Hypothalamic involvement in Huntington's disease: an in vivo PET study. *Brain*, **2008**, 131, 2860-9	11.2	137
335	The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions. *Brain*, **2005**, 128, 584-96	11.2	136
334	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. *Stem Cell Reports*, **2016**, 6, 787-797	8	136
333	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2011**, 10, 1049-57	24.1	134

332	Decreased hippocampal cell proliferation in R6/1 Huntington's mice. *NeuroReport*, **2004**, 15, 811-3	1.7	131
331	Mutant huntingtin is present in neuronal grafts in Huntington disease patients. *Annals of Neurology* , **2014**, 76, 31-42	9.4	130
330	Intracellular SERS nanoprobes for distinction of different neuronal cell types. *Nano Letters*, **2013**, 13, 2463-70	11.5	124
329	Biomarkers and Parkinson's disease. *Brain*, **2004**, 127, 1693-705	11.2	122
328	The Cambridge Behavioural Inventory revised. *Dementia E Neuropsychologia*, **2008**, 2, 102-107	2.1	119
327	Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). *Movement Disorders*, **2016**, 31, 995-1003	7	119
326	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. *Journal of Neurology*, **2009**, 256, 493-8	5.5	116
325	Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. *Journal of Neuroscience*, **2005**, 25, 11564-76	6.6	113
324	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. *Brain*, **2014**, 137, 2743-58	11.2	109
323	Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. *Movement Disorders*, **2012**, 27, 1522-9	7	109
322	Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment?. *NeuroImage*, **2010**, 52, 1015-26	7.9	104
321	Imaging microglial activation in Huntington's disease. *Brain Research Bulletin*, **2007**, 72, 148-51	3.9	103
320	New approaches for brain repair-from rescue to reprogramming. *Nature*, **2018**, 557, 329-334	50.4	100
319	Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?. *Movement Disorders*, **2016**, 31, 103-10	7	99
318	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. *Lancet Neurology, The*, **2017**, 16, 620-629	24.1	98
317	Neural grafting in Parkinson's disease Problems and possibilities. *Progress in Brain Research*, **2010**, 184, 265-94	2.9	97
316	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. *Brain*, **2011**, 134, 137-42	11.2	95
315	Neurodegeneration: a failure of neuroregeneration?. *Lancet, The*, **2001**, 358, 1174-6	40	95

314	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. *Parkinsonism and Related Disorders*, **2016**, 27, 47-53	3.6	95
313	Health-related quality of life in Huntington's disease: Which factors matter most?. *Movement Disorders*, **2009**, 24, 574-8	7	94
312	Targeting impulsivity in Parkinson's disease using atomoxetine. *Brain*, **2014**, 137, 1986-97	11.2	93
311	White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. *NeuroImage*, **2012**, 62, 1675-84	7.9	93
310	The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. *Neuropsychologia*, **2010**, 48, 2719-29	3.2	93
309	Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. *Neuroscience Letters*, **2005**, 381, 294-8	3.3	91
308	Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. *Experimental Brain Research*, **1995**, 106, 275-82	2.3	91
307	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. *Movement Disorders*, **2016**, 31, 1518-1526	7	90
306	Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. *CNS Drugs*, **2006**, 20, 477-505	6.7	90
305	The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. *Journal of Neurology*, **2005**, 252, 833-8	5.5	90
304	The spectrum of cognitive impairment in Lewy body diseases. *Movement Disorders*, **2014**, 29, 608-21	7	89
303	Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. *Nature Medicine*, **2019**, 25, 1045-1053	50.5	88
302	Habitual versus goal-directed action control in Parkinson disease. *Journal of Cognitive Neuroscience*, **2011**, 23, 1218-29	3.1	88
301	Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. *Parkinsonism and Related Disorders*, **2014**, 20, 1071-5	3.6	87
300	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. *Neuropsychologia*, **2008**, 46, 2152-60	3.2	84
299	Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. *Neuropsychologia*, **2002**, 40, 1277-84	3.2	81
298	The role of tau in the pathological process and clinical expression of Huntington's disease. *Brain*, **2015**, 138, 1907-18	11.2	80
297	Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. *Cell Cycle*, **2009**, 8, 2888-94	4.7	80

296	Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. *Experimental Brain Research*, **2006**, 174, 7-18	2.3	78
295	Microfluidic Neural Devices: 3D-Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices (Adv. Sci. 16/2020). *Advanced Science*, **2020**, 7, 2070088	13.6	78
294	Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. *Brain*, **2014**, 137, 1145-55	11.2	77
293	Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. *European Journal of Neuroscience*, **2014**, 39, 1042-1056	3.5	77
292	Clinical translation of stem cells in neurodegenerative disorders. *Cell Stem Cell*, **2012**, 10, 151-5	18	76
291	Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. *Current Neurology and Neuroscience Reports*, **2011**, 11, 211-7	6.6	76
290	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. *Brain Research Bulletin*, **2008**, 76, 70-9	3.9	75
289	Sleep deficits but no metabolic deficits in premanifest Huntington's disease. *Annals of Neurology*, **2015**, 78, 630-48	9.4	70
288	Huntington's disease patients have selective problems with insight. *Movement Disorders*, **2006**, 21, 385-97		70
287	Improving response inhibition in Parkinson's disease with atomoxetine. *Biological Psychiatry*, **2015**, 77, 740-8	7.9	69
286	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. *Movement Disorders*, **2019**, 34, 1839-1850	7	69
285	Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. *American Journal of Neuroradiology*, **2010**, 31, 1036-41	4.4	69
284	Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. *ACS Nano*, **2016**, 10, 307-16	16.7	67
283	Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease. *Human Gene Therapy Clinical Development*, **2018**, 29, 148-155	3.2	67
282	A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. *Journal of Experimental Medicine*, **2012**, 209, 1-10	16.6	65
281	A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. *Journal of Neuroscience*, **2000**, 20, 3415-24	6.6	64
280	Top-down attentional control in Parkinson's disease: salient considerations. *Journal of Cognitive Neuroscience*, **2010**, 22, 848-59	3.1	63
279	Anti-amyloid compounds inhibit □synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). *Journal of Biological Chemistry*, **2014**, 289, 11897-11905	5.4	62

278	Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. *European Journal of Neuroscience*, **2002**, 15, 1255-66	3.5	62
277	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. *European Journal of Neuroscience*, **2019**, 49, 328-338	3.5	60
276	Neurotrophic factors as a therapeutic target for Parkinson's disease. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 437-47	6.4	60
275	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. *Neurobiology of Aging*, **2016**, 48, 153-160	5.6	60
274	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. *Lancet Neurology, The*, **2016**, 15, 585-96	24.1	59
273	Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells. *Neuroscience*, **2001**, 106, 201-16	3.9	59
272	Atomoxetine restores the response inhibition network in Parkinson's disease. *Brain*, **2016**, 139, 2235-48	11.2	57
271	REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. *EMBO Molecular Medicine*, **2017**, 9, 1117-1131	12	57
270	Review: The spectrum of clinical features seen with alpha synuclein pathology. *Neuropathology and Applied Neurobiology*, **2016**, 42, 6-19	5.2	56
269	Features of -associated Parkinson's disease at presentation in the UK study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 702-709	5.5	55
268	Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). *Progress in Brain Research*, **2017**, 230, 165-190	2.9	55
267	The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. *European Journal of Neurology*, **2013**, 20, 1325-9	6	54
266	Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. *Hippocampus*, **2011**, 21, 233-8	3.5	54
265	Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes. *Methods*, **2014**, 68, 354-63	4.6	53
264	Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. *Brain Research*, **2007**, 1151, 219-26	3.7	53
263	A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. *EMBO Journal*, **2016**, 35, 1963-78	13	52
262	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. *Brain*, **2012**, 135, 2449-57	11.2	52
261	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. *Brain*, **2016**, 139, 161-73	11.2	51

260	Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity. *Journal of Clinical Neuroscience*, **2009**, 16, 620-5	2.2	50
259	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. *Movement Disorders*, **2012**, 27, 312-5	7	49
258	Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. *Neuropsychologia*, **2009**, 47, 1117-27	3.2	49
257	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. *Neurobiology of Disease*, **2010**, 37, 356-61	7.5	49
256	Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. *Journal of Neurology*, **2009**, 256, 203-12	5.5	48
255	The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. *Neuropsychology*, **2006**, 20, 578-88	3.8	48
254	Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. *Journal of Parkinson's Disease*, **2016**, 6, 57-63	5.3	47
253	Molecular and functional definition of the developing human striatum. *Nature Neuroscience*, **2014**, 17, 1804-15	25.5	47
252	The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study. *Brain and Behavior*, **2015**, 5, e00312	3.4	46
251	Patients beware: commercialized stem cell treatments on the web. *Cell Stem Cell*, **2010**, 7, 43-9	18	46
250	Predictors of punding in Parkinson's disease: results from a questionnaire survey. *Movement Disorders*, **2007**, 22, 2339-45	7	46
249	The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. *Cell Transplantation*, **2007**, 16, 461-74	4	45
248	Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. *European Journal of Neurology*, **2017**, 24, 357-365	6	44
247	Dopamine and Huntington's disease. *Expert Review of Neurotherapeutics*, **2015**, 15, 445-58	4.3	43
246	Determinants of delayed diagnosis in Parkinson's disease. *Journal of Neurology*, **2013**, 260, 1978-81	5.5	43
245	The use of quantitative oculometry in the assessment of Huntington's disease. *Experimental Brain Research*, **2006**, 169, 237-45	2.3	43
244	WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. *Nature Communications*, **2019**, 10, 1498	17.4	42
243	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. *Human Brain Mapping*, **2016**, 37, 1026-37	5.9	42

242	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. *Neurobiology of Disease*, **2011**, 43, 79-85	7.5	42
241	How vital is sleep in Huntington's disease?. *Journal of Neurology*, **2010**, 257, 882-97	5.5	42
240	No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. *American Journal of Human Genetics*, **2006**, 78, 1088-90; author reply 1092-4	11	42
239	Coping processes and health-related quality of life in Parkinson's disease. *International Journal of Geriatric Psychiatry*, **2011**, 26, 247-55	3.9	41
238	Huntington's disease: changes in saccades and hand-tapping over 3 years. *Journal of Neurology*, **2010**, 257, 1890-8	5.5	41
237	Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?. *Journal of Comparative Neurology*, **2014**, 522, 2802-16	3.4	40
236	Cellular and molecular aspects of striatal development. *Brain Research Bulletin*, **2001**, 55, 533-40	3.9	40
235	GSK-3-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions. *Cell Death and Disease*, **2016**, 7, e2206	9.8	40
234	Cells of the human intestinal tract mapped across space and time. *Nature*, **2021**, 597, 250-255	50.4	40
233	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 512-519	5.5	38
232	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. *Movement Disorders*, **2016**, 31, 1020-6	7	38
231	Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. *Progress in Neurobiology*, **2013**, 110, 63-73	10.9	38
230	Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease. *Scientific Reports*, **2017**, 7, 5280	4.9	38
229	Cell-based therapies for Parkinson's disease. *Expert Review of Neurotherapeutics*, **2011**, 11, 831-44	4.3	38
228	Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. *NeuroImage*, **2009**, 47, 1659-65	7.9	38
227	Survival of Nigral Grafts within the Striatum of Marmosets with 6-Ohda Lesions Depends Critically on Donor Embryo Age. *Cell Transplantation*, **1997**, 6, 557-569	4	38
226	The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. *Psychopharmacology*, **2008**, 197, 279-93	4.7	38
225	The cellular repair of the brain in Parkinson's disease--past, present and future. *Transplant Immunology*, **2004**, 12, 321-42	1.7	38

224	Exploring causality of the association between smoking and Parkinson's disease. *International Journal of Epidemiology*, **2019**, 48, 912-925	7.8	38
223	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. *Cell Reports*, **2018**, 24, 1397-1406	10.6	37
222	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. *Lancet Neurology, The*, **2012**, 11, 643-50	24.1	37
221	Saccadometry: a new tool for evaluating presymptomatic Huntington patients. *NeuroReport*, **2007**, 18, 1133-6	1.7	37
220	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2016**, 33, 96-101	3.6	36
219	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. *Movement Disorders*, **2016**, 31, 1062-6	7	36
218	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. *Brain*, **2019**, 142, 2828-2844	11.2	35
217	Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?. *Frontiers in Neuroscience*, **2017**, 11, 530	5.1	35
216	Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. *Cell Death and Differentiation*, **2011**, 18, 907-13	12.7	34
215	Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. *Experimental Brain Research*, **2003**, 151, 204-17	2.3	34
214	The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. *Neurobiology of Aging*, **2010**, 31, 1064-8	5.6	33
213	Hippocampal dysfunction defines disease onset in Huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 975-81	5.5	32
212	Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. *Brain*, **2013**, 136, 433-43	11.2	32
211	Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. *Journal of Parkinsonfs Disease*, **2013**, 3, 231-9	5.3	32
210	The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. *Journal of Neurology*, **2005**, 252, 642-7	5.5	32
209	Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. *Journal of Cognitive Neuroscience*, **2003**, 15, 629-42	3.1	32
208	Recent developments in the treatment of Parkinson's Disease. *F1000Research*, **2020**, 9,	3.6	32
207	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. *Parkinsonism and Related Disorders*, **2017**, 36, 63-68	3.6	31

206	Development and external validation of a prognostic model in newly diagnosed Parkinson disease. *Neurology*, **2016**, 86, 986-93	6.5	31
205	Tracking Parkinson's: Study Design and Baseline Patient Data. *Journal of Parkinson's Disease*, **2015**, 5, 947-59	5.3	31
204	Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. *Movement Disorders*, **2012**, 27, 1173-7	7	31
203	Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project. *Cell Transplantation*, **2000**, 9, 235-46	4	31
202	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. *Neurobiology of Aging*, **2017**, 55, 78-90	5.6	30
201	Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. *Neurobiology of Aging*, **2015**, 36, 1519-28	5.6	30
200	The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease. *Neuropsychologia*, **2015**, 70, 80-9	3.2	30
199	C-PE2I and F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. *Movement Disorders*, **2018**, 33, 117-127	7	30
198	Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. *Human Brain Mapping*, **2017**, 38, 1702-1715	5.9	29
197	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. *Brain, Behavior, and Immunity*, **2020**, 87, 473-488	16.6	29
196	Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). *Journal of Parkinson's Disease*, **2014**, 4, 671-6	5.3	29
195	Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation. *Neurobiology of Disease*, **2011**, 41, 407-14	7.5	29
194	Successful treatment of stiff man syndrome with intravenous immunoglobulin. *Journal of Neurology, Neurosurgery and Psychiatry*, **1997**, 62, 426-7	5.5	29
193	The search for a curative cell therapy in Parkinson's disease. *Journal of the Neurological Sciences*, **2008**, 265, 32-42	3.2	29
192	Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. *Cell Transplantation*, **2003**, 12, 687-95	4	29
191	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. *Journal of Parkinson's Disease*, **2020**, 10, 875-891	5.3	28
190	Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. *Experimental Neurology*, **2016**, 285, 72-81	5.7	28
189	Developing stem cell therapies for Parkinson's disease: waiting until the time is right. *Cell Stem Cell*, **2014**, 15, 539-42	18	28

188	Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies. *Journal of Parkinson's Disease*, **2013**, 3, 45-53	5.3	28
187	The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. *Neurobiology of Disease*, **2007**, 25, 594-608	7.5	28
186	Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. *Journal of Neurology*, **2008**, 255, 1145-52	5.5	28
185	The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease. *Frontiers in Neurology*, **2018**, 9, 946	4.1	28
184	The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?. *Frontiers in Pharmacology*, **2014**, 5, 139	5.6	27
183	Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease. *Neuropsychologia*, **2006**, 44, 1290-304	3.2	27
182	Repairing the brain in Parkinson's disease: where next?. *Movement Disorders*, **2002**, 17, 233-41	7	27
181	Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. *Cell Transplantation*, **2000**, 9, 743-9	4	27
180	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. *Stem Cell Reports*, **2021**, 16, 1398-1408	8	27
179	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 424-433	7	27
178	The effects of modafinil on mood and cognition in Huntington's disease. *Psychopharmacology*, **2008** , 199, 29-36	4.7	26
177	Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. *Brain*, **2019**, 142, 2023-2036	11.2	25
176	A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. *Cell Transplantation*, **1995**, 4, 173-200	4	25
175	Successful treatment of intractable epilepsia partialis continua with multiple subpial transections. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 65, 137-8	5.5	25
174	Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. *Journal of Neurology*, **2018**, 265, 1528-1539	5.5	24
173	The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease. *Journal of Neurology*, **2013**, 260, 2777-85	5.5	24
172	Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. *Neurobiology of Disease*, **2013**, 49, 118-27	7.5	24
171	Current status of clinical trials of neural transplantation in Parkinson's disease. *Progress in Brain Research*, **2012**, 200, 169-98	2.9	24

170	Parkinson's disease and healthy aging: independent and interacting effects on action selection. *Human Brain Mapping*, **2010**, 31, 1886-99	5.9	24
169	The search for biomarkers in Parkinson's disease: a critical review. *Expert Review of Neurotherapeutics*, **2008**, 8, 1841-52	4.3	24
168	Neural grafting for Parkinson's disease: challenges and prospects. *Neural Regeneration Research*, **2017**, 12, 389-392	4.5	24
167	The Dementias Platform UK (DPUK) Data Portal. *European Journal of Epidemiology*, **2020**, 35, 601-611	12.1	23
166	Graft-induced dyskinesias in Parkinson's disease: what is it all about?. *Cell Stem Cell*, **2010**, 7, 148-9	18	23
165	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. *Science Advances*, **2021**, 7,	14.3	23
164	Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 41-52	4	22
163	Mild cognitive impairment and Parkinson's disease--something to remember. *Journal of Parkinsonfs Disease*, **2014**, 4, 651-6	5.3	22
162	Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion. *Journal of Neurology*, **1997**, 244, 204-7	5.5	22
161	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. *Journal of Parkinsonfs Disease*, **2020**, 10, 193-206	5.3	22
160	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. *Frontiers in Neurology*, **2018**, 9, 870	4.1	22
159	The incidence of Parkinson's disease in the North-East of England. *Age and Ageing*, **2014**, 43, 257-63	3	21
158	Biomarkers in Huntington's and Parkinson's Disease. *Annals of the New York Academy of Sciences*, **2009**, 1180, 97-110	6.5	21
157	Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. *Cell Transplantation*, **2003**, 12, 679-86	4	21
156	The future of cell-based transplantation therapies for neurodegenerative disorders. *Journal of Hematotherapy and Stem Cell Research*, **2003**, 12, 635-42		21
155	Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. *Acta Neurologica Scandinavica*, **2016**, 134, 271-6	3.8	20
154	Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. *PLoS ONE*, **2012**, 7, e32830	3.7	20
153	Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. *Clinical Pharmacology and Therapeutics*, **2008**, 83, 663-5	6.1	20

152	Quality of life and mild cognitive impairment in early Parkinson's disease: does subtype matter?. *Journal of Parkinson's Disease*, **2014**, 4, 331-6	5.3	19
151	Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease. *Journal of Neurology*, **2007**, 254, 846-8	5.5	19
150	Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. *Movement Disorders*, **2020**, 35, 185-190	7	19
149	3D-Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices. *Advanced Science*, **2020**, 7, 2001150	13.6	18
148	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. *Movement Disorders Clinical Practice*, **2017**, 4, 509-516	2.2	18
147	The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review. *Frontiers in Integrative Neuroscience*, **2011**, 5, 78	3.2	18
146	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. *Journal of Parkinson's Disease*, **2016**, 6, 289-300	5.3	18
145	Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease. *Neurobiology of Disease*, **2019**, 124, 163-175	7.5	18
144	A roadmap for the Human Developmental Cell Atlas. *Nature*, **2021**, 597, 196-205	50.4	18
143	Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits. *Cortex*, **2017**, 93, 178-192	3.8	17
142	The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?. *Stem Cell Reports*, **2018**, 10, 1429-1431	8	17
141	Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease. *Movement Disorders*, **2020**, 35, 1062-1066	7	16
140	Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. *NeuroReport*, **2006**, 17, 1623-7	1.7	16
139	Migration and differentiation of transplanted human neural precursor cells. *NeuroReport*, **2003**, 14, 1257-62	1.7	16
138	New therapeutic approaches to Parkinson's disease including neural transplants. *Neurorehabilitation and Neural Repair*, **2005**, 19, 155-81	4.7	16
137	Differences in the Presentation and Progression of Parkinson's Disease by Sex. *Movement Disorders* , **2021**, 36, 106-117	7	16
136	An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. *Journal of Neurology*, **2017**, 264, 2457-2463	5.5	15
135	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. *Annals of Neurology*, **2018**, 83, 532-543	9.4	15

134	Rating Apathy in Huntington's Disease: Patients and Companions Agree. *Journal of Huntingtonfs Disease*, **2015**, 4, 49-59	1.9	15
133	The future of cell therapies in the treatment of Parkinson's disease. *Expert Opinion on Biological Therapy*, **2007**, 7, 1487-98	5.4	15
132	Transplanted human neural precursor cells migrate widely but show no lesion-specific tropism in the 6-hydroxydopamine rat model of Parkinson's disease. *Cell Transplantation*, **2006**, 15, 579-93	4	15
131	Animal Models of Parkinson's Disease: Are They Useful or Not?. *Journal of Parkinsonfs Disease*, **2020** , 10, 1335-1342	5.3	15
130	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. *Nature Genetics*, **2021**, 53, 787-793	36.3	15
129	iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. *Experimental Neurobiology*, **2018**, 27, 350-364	4	15
128	Using Medical Claims Analyses to Understand Interventions for Parkinson Patients. *Journal of Parkinsonfs Disease*, **2018**, 8, 45-58	5.3	14
127	Cell therapies for Parkinson's disease: how far have we come?. *Regenerative Medicine*, **2016**, 11, 777-786	2.5	14
126	Learning to be inflexible: Enhanced attentional biases in Parkinson's disease. *Cortex*, **2016**, 82, 24-34	3.8	14
125	Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age. *Cell Transplantation*, **1999**, 8, 593-9	4	14
124	A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice. *Frontiers in Neurology*, **2019**, 10, 858	4.1	13
123	Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-Ecatenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. *DMM Disease Models and Mechanisms*, **2014**, 7, 1193-203	4.1	13
122	Stem cells and neurodegenerative diseases: where is it all going?. *Regenerative Medicine*, **2012**, 7, 26-31	2.5	13
121	Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1249-58	4	13
120	Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. *Cell Transplantation*, **2006**, 15, 279-94	4	13
119	A case of unilateral neglect in Huntington's disease. *Neurocase*, **2003**, 9, 261-73	0.8	13
118	Migration of cells from primary transplants of allo- and xenografted foetal striatal tissue in the adult rat brain. *European Journal of Neuroscience*, **2005**, 21, 1503-10	3.5	13
117	Prospects for the treatment of Parkinson's disease using neurotrophic factors. *Expert Opinion on Pharmacotherapy*, **2001**, 2, 1531-43	4	13

116	Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD. *Movement Disorders*, **2019**, 34, 1690-1698	7	12
115	Huntington's disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory. *Cortex*, **2019**, 119, 417-427	3.8	12
114	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. *Journal of Parkinson's Disease*, **2015**, 5, 743-7	5.3	12
113	Retrospective assessment of movement disorder society criteria for mild cognitive impairment in Parkinson's disease. *Journal of the International Neuropsychological Society*, **2015**, 21, 137-45	3.1	12
112	Modelling the natural history of Huntington's disease progression. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1143-9	5.5	12
111	Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. *Neurobiology of Disease*, **2014**, 66, 19-27	7.5	12
110	Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. *Movement Disorders*, **2010**, 25, 888-95	7	12
109	Established and emerging therapies for Huntington's disease. *Current Molecular Medicine*, **2007**, 7, 579-87	2.5	12
108	Regenerative Therapies for Parkinson's Disease: An Update. *BioDrugs*, **2018**, 32, 357-366	7.9	11
107	Parkinson's disease--the continuing search for biomarkers. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 393-401	5.9	11
106	Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease. *Xenotransplantation*, **2006**, 13, 233-47	2.8	11
105	Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. *Xenotransplantation*, **2004**, 11, 60-71	2.8	11
104	Pseudo-neglect in Huntington's disease correlates with decreased angular gyrus density. *NeuroReport*, **2004**, 15, 1061-4	1.7	11
103	Huntingtin-lowering strategies for Huntington's disease. *Expert Opinion on Investigational Drugs*, **2020**, 29, 1125-1132	5.9	11
102	The coding and long noncoding single-cell atlas of the developing human fetal striatum. *Science*, **2021**, 372,	33.3	11
101	Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. *Movement Disorders*, **2016**, 31, 1163-72	7	11
100	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. *Parkinsonism and Related Disorders*, **2019**, 65, 55-61	3.6	10
99	The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series. *Journal of Neurology*, **2018**, 265, 1789-1794	5.5	10

98	A Professional Standard for Informed Consent for Stem Cell Therapies. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1651-1652	27.4	10
97	Dual modulation of neuron-specific microRNAs and the REST complex promotes functional maturation of human adult induced neurons. *FEBS Letters*, **2019**, 593, 3370-3380	3.8	10
96	Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. *Journal of Huntingtonfs Disease*, **2015**, 4, 131-40	1.9	10
95	The factor structure of the UPDRS as an index of disease progression in Parkinson's disease. *Journal of Parkinsonfs Disease*, **2011**, 1, 75-82	5.3	10
94	Pax7 expression in the adult rat superior colliculus following optic nerve injury. *NeuroReport*, **2007**, 18, 105-9	1.7	10
93	Prospects for the treatment of Parkinson's disease using neural grafts. *Expert Opinion on Pharmacotherapy*, **2000**, 1, 889-902	4	10
92	DJ-1 can form □sheet structured aggregates that co-localize with pathological amyloid deposits. *Neurobiology of Disease*, **2020**, 134, 104629	7.5	10
91	Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease. *Chemical Science*, **2020**, 11, 525-533	9.4	10
90	Systemic □synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. *Molecular Psychiatry*, **2021**, 26, 556-567	15.1	10
89	Platelet-derived extracellular vesicles in Huntington's disease. *Journal of Neurology*, **2018**, 265, 2704-2712	5.5	10
88	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. *Parkinsonism and Related Disorders*, **2017**, 40, 40-46	3.6	9
87	Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease. *Stem Cells*, **2020**, 38, 936-947	5.8	9
86	Dopamine stimulates epidermal growth factor release from adult neural precursor cells derived from the subventricular zone by a disintegrin and metalloprotease. *NeuroReport*, **2011**, 22, 956-8	1.7	9
85	Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue. *NeuroReport*, **2002**, 13, 481-5	1.7	9
84	Outcome of cell suspension allografts in a patient with Huntington's disease. *Annals of Neurology*, **2018**, 84, 950-956	9.4	9
83	Categorising Visual Hallucinations in Early Parkinson's Disease. *Journal of Parkinsonfs Disease*, **2018**, 8, 447-453	5.3	8
82	How often does music and rhythm improve patients' perception of motor symptoms in Parkinson's disease?. *Journal of Neurology*, **2013**, 260, 1404-5	5.5	8
81	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. *Neurodegenerative Diseases*, **2015**, 15, 331-8	2.3	8

80	Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: the role of rule reconfiguration. *Journal of Neuropsychology*, **2014**, 8, 53-74	2.6	8
79	Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice. *NeuroReport*, **2010**, 21, 349-53	1.7	8
78	Neurotrophic factors and neural grafts: a growing field. *Seminars in Neuroscience*, **1993**, 5, 431-441		8
77	A new approach to disease-modifying drug trials in Parkinson's disease. *Journal of Clinical Investigation*, **2013**, 123, 2364-5	15.9	8
76	Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. *Movement Disorders*, **2021**, 36, 1772-1780	7	8
75	The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. *Neurotherapeutics*, **2021**, 18, 202-216	6.4	8
74	Rating Apathy in Huntington's Disease: Patients and Companions Agree. *Journal of Huntington's Disease*, **2015**, 4, 49-59	1.9	8
73	A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice. *Journal of Physiology*, **2015**, 593, 2257-78	3.9	7
72	A genome wide linkage disequilibrium screen in Parkinson's disease. *Journal of Neurology*, **2005**, 252, 597-602	5.5	7
71	Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease. *Movement Disorders*, **2020**, 35, 401-408	7	7
70	A blueprint for translational regenerative medicine. *Science Translational Medicine*, **2020**, 12,	17.5	7
69	Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?. *Neurotherapeutics*, **2020**, 17, 1539-1562	6.4	7
68	Formation of hippocampal mHTT aggregates leads to impaired spatial memory, hippocampal activation and adult neurogenesis. *Neurobiology of Disease*, **2017**, 102, 105-112	7.5	6
67	Progress in Huntington's disease: the search for markers of disease onset and progression. *Journal of Neurology*, **2015**, 262, 1990-5	5.5	6
66	Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts. *Journal of Visualized Experiments*, **2018**,	1.6	6
65	A simple assessment model to quantifying the dynamic hippocampal neurogenic process in the adult mammalian brain. *Hippocampus*, **2016**, 26, 517-29	3.5	6
64	Putative cortical dopamine levels affect cortical recruitment during planning. *Neuropsychologia*, **2013**, 51, 2194-201	3.2	6
63	The relationship between abnormalities of saccadic and manual response times in Parkinson's disease. *Journal of Parkinson's Disease*, **2013**, 3, 557-63	5.3	6

62	No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. *Journal of Neurology*, **2009**, 256, 132-3	5.5	6
61	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. *Brain*, **2021**, 144, 2513-2526	11.2	6
60	Early constipation predicts faster dementia onset in Parkinson's disease. *Npj Parkinsonfs Disease*, **2021**, 7, 45	9.7	6
59	Novel targets for Huntington's disease: future prospects. *Degenerative Neurological and Neuromuscular Disease*, **2016**, 6, 25-36	5.4	6
58	Random number generation in patients with symptomatic and presymptomatic Huntington's disease. *Cognitive and Behavioral Neurology*, **2004**, 17, 208-12	1.6	6
57	Parkinson's disease: diagnosis and current management. *The Prescriber*, **2015**, 26, 16-23	0.4	5
56	Spatial structure normalises working memory performance in Parkinson's disease. *Cortex*, **2017**, 96, 73-83	3.8	5
55	Stem cell transplantation as an approach to brain repair. *Expert Opinion on Therapeutic Patents*, **2001**, 11, 1563-1582	6.8	5
54	The rejection of neural xenotransplants: a role for antibodies. *Transplantation*, **1999**, 68, 1091-2	1.8	5
53	Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development. *Cerebral Cortex*, **2019**, 29, 2115-2124	5.1	5
52	Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages. *Value in Health*, **2019**, 22, 712-720	3.3	4
51	Current understanding of the glial response to disorders of the aging CNS. *Frontiers in Pharmacology*, **2012**, 3, 95	5.6	4
50	The neurological assessment of patients in vegetative and minimally conscious states. *Neuropsychological Rehabilitation*, **2005**, 15, 214-23	3.1	4
49	Neural transplantation therapies for Parkinson's and Huntington's diseases. *Drug Discovery Today*, **2001**, 6, 575-582	8.8	4
48	Metastatic non-seminomatous germ cell tumour and dermatomyositis. *Postgraduate Medical Journal*, **1990**, 66, 59-60	2	4
47	The sleep and circadian problems of Huntington's disease: when, why and their importance. *Journal of Neurology*, **2021**, 268, 2275-2283	5.5	4
46	The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington's Disease Patients. *Journal of Huntingtonfs Disease*, **2020**, 9, 275-282	1.9	4
45	Single cell derived mRNA signals across human kidney tumors. *Nature Communications*, **2021**, 12, 3896	17.4	4

44	Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. *Parkinsonism and Related Disorders*, **2016**, 29, 121-2	3.6	4
43	Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease. *Journal of Parkinsonfs Disease*, **2018**, 8, 511-515	5.3	4
42	Movement disorders and psychiatry: Five new things. *Neurology: Clinical Practice*, **2015**, 5, 143-149	1.7	3
41	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 76, 49-53	3.6	3
40	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. *Journal of Parkinsonfs Disease*, **2020**, 10, 1047-1055	5.3	3
39	Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms. *NeuroImage: Clinical*, **2020**, 27, 102277	5.3	3
38	Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis. *Frontiers in Neurology*, **2017**, 8, 156	4.1	3
37	The central clock in patients with Parkinson disease--reply. *JAMA Neurology*, **2014**, 71, 1456-7	17.2	3
36	The challenges of administering cell-based therapies to patients with Parkinson's disease. *NeuroReport*, **2013**, 24, 1000-4	1.7	3
35	Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. *Journal of Anatomy*, **2009**, 214, 396-405	2.9	3
34	Parkinson's disease and 2009: recent advances. *Journal of Neurology*, **2010**, 257, 1224-8	5.5	3
33	Cell-based therapies for disorders of the CNS. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 1361-1376	6.8	3
32	MEIS-WNT5A axis regulates development of 4th ventricle choroid plexus		3
31	Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease. *NeuroImage: Clinical*, **2020**, 28, 102409	5.3	3
30	MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. *Development (Cambridge)*, **2021**, 148,	6.6	3
29	Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease. *Journal of Huntingtonfs Disease*, **2019**, 8, 181-193	1.9	2
28	CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease. *PLoS ONE*, **2017**, 12, e0171748	3.7	2
27	L-dopa responsive parkinsonism secondary to a subdural haematoma. *Journal of Clinical Neuroscience*, **2013**, 20, 1022-4	2.2	2

26	Neurodegenerative disorders: the Glia way forward. *Frontiers in Pharmacology*, **2014**, 5, 157	5.6	2
25	"The eyes have it". Saccadometry and Parkinson's disease. *Experimental Neurology*, **2009**, 219, 382-4	5.7	2
24	Stem cells and regenerative therapies for Parkinson's disease. *Degenerative Neurological and Neuromuscular Disease*, **2012**, 2, 79-92	5.4	2
23	Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach. *Journal of Huntingtonfs Disease*, **2019**, 8, 9-22	1.9	2
22	The future of stem cells in neurodegenerative disorders of the central nervous system. *Cmaj*, **2012**, 184, 631-2	3.5	1
21	Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. *Nature Clinical Practice Neurology*, **2007**, 3, 250-1		1
20	The future challenges in Parkinson's disease. *Journal of Neurology*, **2004**, 251, 361-5	5.5	1
19	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. *Parkinsonism and Related Disorders*, **2021**, 87, 61-69	3.6	1
18	Late-onset Huntington's disease associated with CAG repeat lengths of 30 and 31. *Journal of Neurology*, **2021**, 268, 3916-3919	5.5	1
17	F11 Verbal memory in huntington disease: a longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A52.2-A52	5.5	1
16	Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease. *Movement Disorders*, **2021**, 36, 263-264	7	1
15	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 171-177	7	1
14	Transvascular delivery of synuclein preformed fibrils, using the RVG9R delivery system, generates synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. *Molecular Psychiatry*, **2021**, 26, 365-365	15.1	1
13	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. *Journal of Parkinsonfs Disease*, **2021**, 11, 1297-1308	5.3	1
12	Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective. *Journal of Parkinsonfs Disease*, **2021**, 11, S129-S134	5.3	1
11	Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.. *PLoS Computational Biology*, **2022**, 18, e1010079	5	1
10	Parkinson's disease and spirituality. *NeuroRehabilitation*, **2020**, 46, 31-39	2	0
9	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. *Movement Disorders Clinical Practice*, **2022**, 9, 479-483	2.2	0

8	Informed Consent for Stem Cell-Based Interventions-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 323, 894	27.4
7	The neurology community mourns the passing of Dr. John F. Kurtzke. *Journal of Neurology*, **2016**, 263, 421	5.5
6	PO088 Nigral iron susceptibility in parkinson disease: a longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, A34.4-A35	5.5
5	Can patient-specific transdifferentiated neuronal cells help us understand the cellular pathology of Parkinson disease?. *Future Neurology*, **2013**, 8, 605-607	1.5
4	Neural transplants for parkinson disease: what are the issues?. *Poiesis & Praxis*, **2006**, 4, 129-143	
3	An unusual cause for a painful diplopia. *Postgraduate Medical Journal*, **1998**, 74, 177-8	2
2	The Origins of the Protein Spread in Parkinson's Disease. *Movement Disorders Clinical Practice*, **2021**, 8, 1194-1197	2.2
1	Metacognitive insight into cognitive performance in Huntington's disease gene carriers.. *BMJ Neurology Open*, **2022**, 4, e000268	1.5